• Publications
  • Influence
Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Primary bone tumors are rare, accounting for <0.2% of malignant tumors registered in the EUROCARE database [1]. Different tumors have distinct patterns of incidence. Osteosarcoma and Ewing sarcomaExpand
  • 278
  • 11
  • PDF
Phase II study of imatinib in advanced chordoma.
PURPOSE To explore the antitumor activity of imatinib in patients with advanced platelet-derived growth factor β (PDGFB)/PDGF receptor β (PDGFRB)-positive chordomas. PATIENTS AND METHODS In aExpand
  • 173
  • 7
Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Extraskeletal Ewing sarcoma is covered by other ESMO Guidelines: in general, the same principles for these tumours in children apply to adults. This is also the case for embryonal and alveolarExpand
  • 487
  • 5
  • PDF
Clinical and pharmacologic study of the epirubicin and paclitaxel combination in women with metastatic breast cancer.
PURPOSE A pharmacokinetic interaction may cause increased cardiotoxicity of paclitaxel (PTX) and high cumulative dose of doxorubicin. We tested antitumor activity, tolerability, and pharmacokineticsExpand
  • 36
  • 2
Retroperitoneal Sarcoma: Is It Time to Change the Surgical Policy?
BackgroundComplete tumor resection is the mainstay of treatment for retroperitoneal sarcoma (RPS), but the size and quality of surgical margins for radical resection in RPS are unknown. They areExpand
  • 42
  • 2
Prognostic factors for survival in metastatic renal cell carcinoma: retrospective analysis from 109 consecutive patients.
OBJECTIVE Metastatic renal cell cancer (RCC) portends a bad prognosis, but survival is quite different among different patients. The objective of this study was to determine prognostic factors forExpand
  • 63
  • 1
The “old drug” dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas
SummaryThe aim of this study was to evaluate retrospectively the response rate, progression-free survival and median duration of response to dacarbazine as second/third-line chemotherapy forExpand
  • 39
  • 1
Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy.
INTRODUCTION We investigated the activity and safety of sorafenib, a multitargeted tyrosine-kinase inhibitor, in patients with advanced soft tissue sarcomas (STS). PATIENTS AND METHODS AnExpand
  • 42
  • 1
Twenty-four hour insulin secretion and beta cell NEFA oxidation in type 2 diabetic, morbidly obese patients before and after bariatric surgery
Aims/hypothesisWe have previously demonstrated that type 2 diabetes resolves after bariatric surgery. To study the role of NEFA in the prompt normalisation of beta cell glucose sensitivity, insulinExpand
  • 26
  • 1
Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide.
BACKGROUND Following our previous study of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) intensification in non-Hodgkin's lymphoma (NHL), in the present report we attempted toExpand
  • 30
  • 1